Coherus shares stumble on supply issue

18 September 2024

Californian company Coherus Biosciences (Nasdaq: CHRS) has seen its share price tumble by 24% since Friday.

Coherus disclosed a problem with its supply chain impacting Udenyca (pegfilgrastim-cbqv), a biosimilar of Amgen’s (Nasdaq: AMGN) Neulasta (pegfilgrastim) that is licensed in three formulations - preflled syringe, autoinjector, and preflled syringe co-packaged with an on-body injector.

The company’s USA-based, third-party contract manufacturing organization (CMO) for final packaging recently informed Coherus of its over-commitments and capacity constraints at its final labelling and packaging facility that will cause a temporary Udencya supply interruption.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars